The Evolving Landscape of Dietary Supplements

The U.S. Food and Drug Administration (FDA) is currently weighing potential changes to the regulations governing dietary supplements. The proposal aims to address the growing demand for products marketed for specific wellness goals, such as gut health and muscle growth.

Currently, the FDA requires that dietary ingredients be found in food. Supplement manufacturers are lobbying to relax these standards to incorporate newer substances, including peptides. Kyle Diamantas, the FDA's top food official, noted that while the industry has expanded significantly over the past 30 years, the regulatory framework has remained largely stagnant.

Industry Perspectives and Regulatory Challenges

Many wellness products currently on the market do not meet the strict legal definition of dietary supplements. For example, peptides—often sold as injections or infusions—are increasingly being added to gummies, capsules, and powders. Robert Durkin, a former FDA official now working as a consultant, expressed hope that the agency will broaden its interpretation of dietary ingredients to include substances not traditionally found in food.

Concerns Over Public Safety

Consumer advocates are raising alarms regarding the potential expansion of these rules. Jensen Jose, senior regulatory counsel at the Center for Science in the Public Interest, argued that the FDA should prioritize the safety of the current market rather than permitting a wider array of chemicals and substances.

The supplement industry is vast and challenging to monitor, with the FDA estimating that over 100,000 products are currently available. Notably, the agency does not review these products for safety or efficacy before they reach consumers. Instead, manufacturers bear the responsibility for ensuring product safety and the accuracy of their claims.

Current Regulations and Future Outlook

Supplements are currently regulated as food rather than medicine, exempting them from the rigorous approval processes required for drugs. While they cannot claim to treat diseases, manufacturers often use disclaimers stating their products support general health. Mitch Zeller, who managed supplement issues at the FDA in the 1990s, warned that companies often use carefully worded labeling to imply health benefits while avoiding direct drug claims.

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has indicated an interest in easing restrictions on supplements and related products. The FDA continues to review its guidance on dietary supplements as it balances industry innovation with public health oversight.